immediate feedback

« Back

Ken Fujise, M.D.
Director, Division of Cardiology



Ken Fujise, M.D., F.A.C.C., F.A.C.P., F.A.H.A., F.S.C.A.I.

Ken Fujise, M.D., F.A.C.C., F.A.C.P., F.A.H.A., F.S.C.A.I.
Director, Division of Cardiology
Director, Cardiac Catheterization Laboratory
Director, Interventional Cardiology Fellowship Program
Chair, Cardiology Leadership Council
Professor of Medicine and of Biochemistry and Molecular Biology
John Sealy Distinguished Centennial Chair in Cardiology
Division of Cardiology
Department of Internal Medicine

University of Texas Medical Branch
301 University Blvd.
Galveston, TX 77555-0553
Phone: 409.772.4885
kefujise@utmb.edu

Related web sites:
Research Lab
Clinic Site

Clinical Expertise

  1. Interventional cardiology, including coronary and peripheral intervention
  2. Chronic total occlusion (CTO) intervention
  3. Intravascular imaging including intravascular ultrasound (IVUS) and optical coherence tomography (OCT)
  4. Preventive cardiology
  5. Second opinion on the management of coronary artery disease

Clinic Location

Victory Lakes Specialty Care Center Clinic in League City.

Research Interests

  1. Fortilin, a novel anti-apoptotic molecule
  2. Human Papilloma Virus (HPV) and atherosclerosis
  3. Morelloflavone, an anti-atherosclerotic small molecule from Thai medicinal plants
  4. Cardiac biomarkers

Overview

Dr. Ken Fujise, born and raised in Japan, earned his MD from Kyoto University School of Medicine. His internal medicine training was at Metropolitan Hospital Center and Beth Israel Medical Center (both New York, NY), followed by his general cardiology and interventional cardiology fellowships at Beth Israel Medical Center and University of Texas Health Science Center at Houston, respectively. He underwent two-year molecular biology research fellowship at the Institute of Molecular Medicine for the Prevention of Human Diseases. Dr. Fujise is board-certified in Internal Medicine, Cardiovascular Diseases, Interventional Cardiology, and Cardiac CT Angiography. His clinical motto is to make a positive impact on his patient's life using every encounter he has with the patient.

Dr. Fujise is a physician-scientist. As an interventional cardiologist, Dr. Fujise performs coronary and peripheral interventions with chronic total occlusion (CTO) as special interest. In outpatient clinic, Dr. Fujise maximizes the medical regimen to prevent the progression of heart diseases. In his research laboratory, Dr. Fujise's focus is on the molecular biology of fortilin, an anti-apoptotic molecule discovered and characterized in his laboratory. More specifically, his laboratory has investigated the role of fortilin in atherosclerogenesis and heart failure. His group has also identified a possible link between HPV infection and acceleration of atherosclerosis. Investigation continues to test the causal relationship of HPV infection in atherosclerogenesis. Dr. Fujise and his team have published over 50 articles in peer reviewed journals. Dr. Fujise has been awarded a number of research and educational awards including the American Heart Association (AHA) Scientist Development Award, NIH Mentored Clinical Scientist Development Award (KO8), AHA Established Investigator Award, and Master Teacher Award (UT-Houston). He has been named an inventor of two US patents. Dr. Fujise and his family live on the Galveston Island. Dr. Fujise enjoys his morning swim at the Field House, a recreation and gym facility of UTMB.

Education

Degree Year Institution
M.D. 1987 Kyoto University, School of Medicine
Internship & Residency
Internship (Internal Medicine)
Junior Residency (Internal Medicine)
Senior Residency (Internal Medicine)
 
1987-1988
1988-1989
1989-1990
 
Metropolitan Hospital Center – New York Medical College
Metropolitan Hospital Center – New York Medical College
Beth Israel Medical Center – Mount Sinai School of Medicine
Fellowship
Cardiovascular Disease Fellowship
Research Fellowship (Molecular Biology)
Interventional Cardiology Fellowship
 
1990-1993
1993-1995
1995-1996
 
Beth Israel Medical Center – Mount Sinai School of Medicine
University of Texas health Science Center at Houston and Institute of Molecular Medicine
University of Texas health Science Center at Houston and Memorial Hermann Hospital

Pertinent Publications

  1. Pinkaew D, Le RJ, Chen Y, Eltorky M, Teng BB, Fujise K. Fortilin Reduces Apoptosis in Macrophages and Promotes Atherosclerosis. American journal of Physiology Heart and Circulatory Physiology 2013. PMID 24043250
  2. Chen Y, Fujita T, Zhang D, Doan H, Pinkaew D, Liu Z, Wu J, Koide Y, Chiu A, Lin CJC, Chang JY, Ruan KH, Fujise K: The physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. Journal of Biological Chemistry 2011; 286: 32575-85. PMID: 21795694
  3. Kuo HK, Fujise K: Human papillomavirus and cardiovascular disease among U.S. women in the National Health and Nutrition Examination Survey, 2003-2006. Journal of American College of Cardiology 2011: 58: 2001-6. PMID: 22032713.
  4. Pinkaew D, Hutadilok-Towatana N, Teng BB, Mahabusarakam W, Fujise K. Morelloflavone, a biflavonoid inhibitor of migration-related kinases, ameliorates atherosclerosis in mice. American Journal of Physiology-Heart and Circulation. 2011. In press.
  5. Koide Y, Tonganunt M, Kato Y, and Fujise K. Fortilin-deficiency causes embryonic lethality through the overactivation of BMP4 Pathway. Biochimica et BiophysicaActa 2009;1790:326-38 PMID: 2695948
  6. Graidist P, Yazawa M, Tonganunt M, Nakatomi A, Lin CC, Chang J, Phongdara A, Fujise K. Fortilin binds Ca2+ and blocks Ca2+-dependent apoptosis in vivo. Biochemical Journal 2007; 408(2):181-91. PMID: 2267342
  7. Graidist P, Fujise K, Wanna W, Sritunyalucksana K, Phongdara A: Establishing A Role For Shrimp Fortilin In Preventing Cell Death. Aquaculture 2006; 255:157-164. ISSN: 0044-848
  8. Graidist P, Phongdara A, and Fujise K: Anti-apoptotic protein partners fortilin and MCL1 independently protect cells from 5-FU-induced cytotoxicity: Fortilin-MCL1 interaction in apoptosis. Journal of Biological Chemistry 2004; 279:40868-40875. PMID: 15262975
  9. Mnjoyan ZH, Dutta R, Zhang D, Teng BB, and Fujise K: Paradoxical upregulation of tumor suppressor protein p53 in serum-stimulated vascular smooth muscle cells. Circulation 2003; 108:4:464-471. PMID: 12860918
  10. Tulis DA, Mnjoyan ZH, Schiesser R, Shelat HS, Zoldehelyi P, Fujise K: Adenoviral gene transfer of fortilin attenuates neointima formation through suppression of vascular smooth muscle cell proliferation and migration. Circulation 2003; 107:98-105. PMID: 12515750
  11. Zhang D, Li F, Mnjoyan ZH, Weidner D, Fujise K: Physical and functional interaction between MCL1 and fortilin. The potential role of MCL1 as a fortilin chaperone. Journal of Biological Chemistry 2002; 227 (40):37430-37438. PMID
  12. Li F, Zhang D and Fujise K: Characterization of fortilin, a novel anti-apoptotic protein. Journal of Biological Chemistry 2001;276(50):47542-47549. PMID: 11598139
  13. Fujise K, Zhang D, Liu JL and Yeh ETH: Regulation of apoptosis and cell cycle progression by MCL1. Differential role of MCL1. Journal of Biological Chemistry 2000, 275(50):39458-65. PMID: 10978339
  14. Gong L, Kamitani T, Fujise K, Caskey LS, Yeh ETH: Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9. Journal of Biological Chemistry: 1997, 272(45)28198-201. PMID: 9353268
  15. Fujise K, Stacy L, Beck P, Yeh ETH, Chuang A, Brock TA, Willerson JT: Differential effects of endothelin receptor activation on cyclic flow variations in rat mesenteric arteries. Circulation 1997; 96(10);3641-6. PMID: 9396466
  16. Fujise K, Revelle M, Stacy L, Willerson JT, Beck P: A tPA/P-selectin fusion protein is an effective thrombolytic agent. Circulation 1997; 95:715-722. PMID: 9024162

The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.

Currently available protocols are:
  • CAP - Community Acquired Pneumonia Orderset
  • Congestive Heart Failure (CHF)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Diabetic Ketoacidosis Adult, ICU
  • General Medicine Admission
  • Immunodeficiency Flow Panel
  • MICU/CCU Admission Order Set
  • Oral Analgesic Medicaitons
  • Parenteral Opioids
  • Sepsis, Adult ICU
  • 111 - Stroke Alert
  • 112 - Stroke Activation
  • 300086 - Stroke Floor Admission
  • 3000000001 -  Stroke Critical care without tPA
  • 300088 Stroke - Transfer from Critical care to floor
  • 3004002 - Stroke Discharge

All protocols can be found in the EPIC order set section.

» For more information

Meaning Use logo

The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.

Site Managed by UTMB Information Design Services.